We offer a patient-centered approach to care at the University of Illinois Brain Tumor Center, providing
care for persons with all types of tumors that affect the brain or spinal cord. We also offer care for
persons with neurologic complications of cancer or its treatment. Because no two people have the same
needs, our highly specialized team provides individualized services. Care is delivered in a compassionate,
family-focused environment with the highest quality of care, education and support as our primary
goals. Our advanced diagnostic and treatment facilities offer innovative services that allow us to rapidly
apply research findings into our clinical practice.
The UIC Department of Neurology and Rehabilitation Brain Tumor Center specializes in the treatment and support of patients who suffer from a wide array of brain tumors. M. Kelly Nicholas, MD, PhD, is the service director of neuro-oncology in the Department of Neurology and Rehabilitation at UIC. He works as a member of a multidisciplinary team to provide expert care to people living with brain tumors and to those experiencing neurological side effects of cancer treatment. He oversees a number of clinical trials in an effort to improve the lives of those he serves.
We work closely with our colleagues in neurosurgery, radiation oncology, and neuropsychology to
provide multidisciplinary care. These specialists meet weekly to review and revise patient treatment
plans. Nurses, technicians, residents, and fellows also provide valuable contributions to care.
Standard of care treatments exist for every tumor type, but options can be limited. For this reason,
clinical trials are an essential component of care. To learn more about brain tumor clinical trials offered
at the University of Illinois, call Jean Arzbaecher at (312)-996-3369 or send an email to: email@example.com or review these links:
Friedman, H.S., Prados, M.D., Wen, P.Y., Mikkelsen, T., Schiff, D., Abrey, L.E., Yung, W.K., Paleologos, N., Nicholas, M.K., Jensen, R., Vredenburgh, J., Huang, J., Zheng, M., & Cloughesy, T. (2009).
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Journal of Clinical Oncology, 27(28), 4733-40.
Wefel, J.S., Cloughesy, T., Zazzali, J.L., Zheng, M., Prados, M., Wen, P.Y., Mikkelsen, T., Schiff, D., Abrey, L.E., Yung, W.K., Paleologos, N., Nicholas, M.K., Jensen, R., Vredenburgh, J., Das, A., & Friedman, H.S. (2011).
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.
Neuro-Oncology, 13(6), 60-8
O'Donnell, P.H., Undevia, S.D., Stadler, W.M., Karrison, T.M., Nicholas, M.K., Janisch, L., & Ratain, M.J. (2012).
A phase I study of continuous infusion cilengitide in patients with solid tumors.
Investigation of New Drugs, 30(2), 604-10
Tye, K., Engelhard, H.H., Slavin, K.V., Nicholas, M.K., Chmura, S.J., Kwok, Y., Ho, D.S., Weichselbaum, R.R., & Koshy, M. (2014).
An analysis of radiation necrosis of the central nervous system treated with bevacizumab.
Journal of Neuro-Oncology, 117(2), 321-7
Liang, Y., Diehn, M., Bollen, A.W., Aldape, K.D., Nicholas, M.K., Lamborn, K.R., Berger, M.S., Botstein, D., Brown, P.O., & Israel, M.A. (2005).
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme.
Proceedings of the National Academy of Science, 102(16), 5814-5819, 2005.
Nicholas MK, Lukas RV, Chmura S, Yamini B, Lesniak M, Pytel P.
Molecular heterogeneity in glioblastoma: opportunities and challenges.
Semin Oncol. 2011 Apr;38(2):243-53.